anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent studies have demonstrated that consuming high fructose corn syrup (HFCS)- or sucrose-sweetened beverages increased lipid/lipoprotein risk factors for cardiovascular disease (CVD) in healthy adults compared with iso-caloric amounts of glucose or low-fat milk. The longest of these studies, which utilized a 6-month intervention, also showed increased liver and muscle TG and increased visceral adipose deposition. Neither of these studies found differences in weight gain between subjects consuming HFCS/sucrose beverages compared with control beverages. These results suggest that it is not just excess calories and weight gain that mediate the effects of dietary sugar/fructose on the development of metabolic disease; rather, dietary sugar per se is also a contributor. However, it is not known whether consumption of excessive amounts of sugar can increase risk factors for metabolic disease in the absence of positive energy balance and weight gain, nor whether the adverse effects of sugar consumption are exacerbated by weight gain. This study will compare the contribution of sugar with the contribution of energy level to the increases in risk factors for metabolic disease induced by consumption of HFCS-sweetened beverages under energy-balanced or ad libitum conditions. The investigators will measure risk factors and processes associated with metabolic disease in 4 groups of young, healthy adults who will consume 1) 0%, 2) or 25% of energy requirement as HFCS-sweetened beverages for 8 weeks with an energy-balanced diet for 6 weeks; 3) 0%, or 4) 25% of energy requirement as HFCS-sweetened beverages for 8 weeks with an ad libitum diet for 6 weeks. All diets, formulated to achieve a comparable macronutrient intake (55% energy as carbohydrate, 35% fat, 15% protein) among all 4 experimental groups, will be provided to the subjects throughout the entire study. The investigators hypothesize that under energy balanced (EB) condition that prevent body weight gain, consumption of HFCS-sweetened beverages will result in adverse metabolic effects compared with aspartame-sweetened beverages. Consumption of HFCS-sweetened beverages with the ad libitum (AL) diet will result in increased energy intake and body weight gain compared with aspartame-sweetened beverages, and will also result in adverse metabolic effects that are more marked than with consumption of HFCS-sweetened beverages with the energy-balanced diet. These results will demonstrate that consumption of HFCS-sweetened beverages increases risk for metabolic disease both directly, via the adverse effects of fructose on lipid and carbohydrate metabolism, and indirectly, via the effects of HFCS-sweetened beverages to promote excess energy intake and body weight gain. These findings will have the potential to influence dietary guidelines and public health policy.
CFI-400945 is a selective oral polo-like kinase 4 (PLK4) inhibitor that regulates centriole duplication. PLK4 is aberrantly expressed in patients with acute myeloid leukemia (AML). Preclinical studies indicate that CFI-400945 has potent in vivo efficacy in hematological malignancies and xenograft models, with activity in cells harboring TP53 mutations. In this phase 1 study in very high-risk patients with relapsed/refractory AML and myelodysplastic syndrome (MDS) (NCT03187288), 13 patients were treated with CFI-400945 continuously in dose escalation from 64 mg/day to 128 mg/day. Three of the 9 efficacy evaluable AML patients achieved complete remission (CR). Two of 4 AML patients (50%) with TP53 mutations and complex monosomal karyotype achieved a CR with 1 patient proceeding to allogenic stem cell transplant. A third patient with TP53 mutated AML had a significant reduction in marrow blasts by > 50% with an improvement in neutrophil and platelet counts. Responses were observed after 1 cycle of therapy. Dose-limiting toxicity was enteritis/colitis. A monotherapy and combination therapy study with a newer crystal form of CFI-400945 in patients with AML, MDS and chronic myelomonocytic leukemia (CMML) is ongoing (NCT04730258).
Uveitis, including iritis and iridocyclitis, has been reported in patients treated with BRAFTOVI in combination with binimetinib. In COLUMBUS, the incidence of uveitis among patients treated with BRAFTOVI in combination with binimetinib was 4%. In PHAROS, the incidence of uveitis among patients treated with BRAFTOVI in combination with binimetinib was 1%.

Assess for visual symptoms at each visit. Perform an ophthalmologic evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction [see Dosage and Administration (2.5), Adverse Reactions (6.1)].
NEW MATERIAL:A compound having the amino acid sequence of formula or one of the amino acid sequences corresponding to sequences produced by successively removing four amino acids from its C-terminal one by one. USE:Remedy for immunoinsufficiency and antitumor agent. PREPARATION:For example, human actuate myelocytic leukemia cell is cultured, the cultured cell is lyzed and the whole RNA fraction is separated by ultracentrifugal separation. The separated fraction is treated with an oligo(dT) cellulose column to separate a poly(A)mRNA, which is used as a template for producing cDNA with a reverse tanscriptase. The cDNA is linked with a plasmid in the presence of an enzyme and the obtained recombinant plasmid is inserted into a host such as E.coli to effect the transformation of the host. The host cell is cloned and the transformed microorganism is cultured. The objective compound of formula can be separated from culture liquid.
The present invention relates to a formula and a preparation method, which belongs to the external use medicine prepared from pure Chinese medicines. More than ten medicines of ephedrae, cassia twig, radix aconiti, kusnezoff monkshood root, angelica, etc. are used for refining an external use medicine bag, medicine plaster and liniment by the special technology. Moreover, the medicine has no toxic or side effect for long term use. Furthermore, the medicine has better effect on preventing and treating diseases of blood stasis and deficient cold, such as rheumatoid arthritis, hyperosteogeny, cervical spondylosis, lumbago and scelalgia, rheumatic heart disease, angina pectoris, coronary disease, chronic hepatitis, chronic nephritis, uremia, asthma, edema, leg turgescence, abdominal distention, vasculitis, dysmenorrhoea, chronic muscle strain, hyperplasia of prostate, nocturia, women postpartum anuresis, etc. The medicine has the advantages of high cure rate, low relapse rate and convenient use, and consequently, patients can gladly accept the medicine.
The present invention relates to a method and kit for inducing tolerance to certain substances causing allergy, and a method for acquiring the tolerance using them. The tolerance induction method and kit comprises a first step for the induction of tolerance and a second step for the confirmation of tolerance induction. In the tolerance induction method, the first step for tolerance induction comprises administering the IFN-y-containing composition to the patient with allergy to certain substances in a given unit per body surface area, and at the same time, administering the substances while gradually increasing the amount of the substances. The second step for the confirmation of tolerance induction comprises administering only the allergens during a given period while increasing the amount of the allergens as in the first step for tolerance induction, without administering the IFN-y-containing composition. The tolerance induction kit comprises an INF-y-containing composition of a quantity to be administered in the first step for the induction of tolerance, allergy-causing substances of a quantity to be administered together with the INF-y-containing composition in the first step for tolerance induction, and allergy-causing substances of a quantity to be administered in a second step for the confirmation of tolerance induction. The tolerance induction method and kit of the present invention, and the method for acquiring tolerance using them, advantageously allow tolerance to certain allergens to be effectively induced, and since then, allow the tolerance to be maintained lastingly even upon the ordinary administration of the allergens.
A method implements healthcare virtualization. The method includes receiving a source event at a collection address from a source system. The source event corresponds to a source record stored by the source system and includes a source patient identifier and a timestamp. The method further includes normalizing the source event to generate a normalized event using a processor to extract a key value pair from the source event. The normalized event federated to the source system. The normalized event includes the source patient identifier and the timestamp. The method further includes matching a unique patient identifier to the source patient identifier to form a matched event federated to the source system and consolidating the matched event to form a consolidated event federated to the source system. The method further includes transmitting the consolidated event to a subscriber system using a subscription address.
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably to immunology, otolaryngology and can be used for chronic tonsillitis treatment in patients with immunodeficiency. Method includes sublingual administration of Imudon. Additionally leech therapy in form of medicinal leech application on skin of palatine tonsils projection in mandibular angle area, one leech per side, is performed. Treatment is performed 2 times a week during 3 month, by course 2 times a year, spring and autumn, 2 year in succession. ^ EFFECT: invention improves treatment effectivity due to effective arrest of chronic tonsillitis exacerbation, recovery of changed immune status, reduction of exacerbations frequency. ^ 1 tbl, 1 ex
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the development of pharmaceutical composition with broad spectrum of pharmacological effect based on derivatives of orotic acid. Invention proposes the composition containing a mixture of potassium orotate and magnesium orotate taken in the definite ratio and accessory substances also and this composition can be used as capsules, dragee or tablets. Invention expands assortment of drugs used in treatment of ischemic heart disease being without any adverse effects. EFFECT: valuable medicinal properties of composition. 3 cl, 2 ex
Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
The 0% formulation of OPA-15406 venicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
The invention relates to sugar-free compound colla corii asini pulp and a preparation process thereof. Existing compound colla corii asini pulp contains saccharose and is not suitable for patients with hyperglycemia and diabetes to take. The sugar-free compound colla corii asini pulp provided by the invention is prepared from the following raw materials: colla corii asini, ginseng, prepared rehmannia roots, codonopsis pilosula and the like as well as a stevia rebaudiana extract and a lemon-grass extract according to a new process. The preparation process of the sugar-free compound colla corii asini pulp comprises the following steps: first, immersing ginseng into 45% ethanol; then, adding into a high-pressure alcohol extraction tank; then, inflating and pressurizing the high-pressure alcohol extraction tank to 8-10kgf/<cm2>; soaking for 2 hours; then, placing in a tank body of a novel traditional Chinese medicine extractor. Meanwhile, the liquid medicine is concentrated by preferably adopting a membrane concentration device. The sugar-free compound colla corii asini pulp provided by the invention is suitable for patients with hyperglycemia and diabetes to take; a novel high-normal pressure alcohol extraction/aqueous extraction mixed extraction process is adopted in the preparation process for the liquid medicine raw materials to extract effective components such as ginseng and the like to the maximum extent, so that the effective components of the components are not lost.
Vitiligo is a chronic disease that causes loss of melanocyte and pigment of the skin. Traditional treatments for vitiligo including topical corticosteroids and phototherapy lead to limited clinical effects. Autologous melanocyte transplantation is another way to treat vitiligo. However, the effect is largely affected by whether cultivated melanocytes are successfully uptaken by vitiliginous skin. The aim of this study is to survey the self-assembly on biomaterials and functional analysis. In the long run, this study may provide a better way for treatment of vitiligo.
INTRODUCTION: Many risk factors for proximal junctional kyphosis (PJK) have been reported in the literature, especially sagittal alignment modifications, but studies on pelvic tilt (PT) variations and its influence on PJK are missing. Aim of this study was to analyze the influence of pelvic tilt correction, after long fusion surgery for ASD patients, on PJK occurrence.
METHODS: A monocentric retrospective study was conducted on prospectively collected data, including 76 patients, operated with fusion extending from the thoraco-lumbar junction to the ilium. Radiologic parameters were measured on fullspine standing radiographs preoperatively, postoperatively (<6 months) and at latest follow-up (before revision surgery or >2 years). All parameters were analyzed comparing patients with PJK (group "PJK") and without PJK (group "no PJK"). A further analysis compared patients with low (PT/PI<25th percentile, LowPT group) and high (PT/PI>75th percentile, HighPT group) preoperative pelvic tilt.
RESULTS: « PJK » patients had a greater lumbar lordosis and thoracic kyphosis correction (p=0,03 et <0,001 respectively) compared to the "no PJK" patients. Pelvic tilt was significantly lower postoperatively in the "PJK" group (p=0,03). Patients from the HighPT PJK group were significantly more corrected than patients from the HighPT noPJK group (p=0,003).
CONCLUSION: Through the analysis of 76 patients, we showed that pelvic tilt did not seem to play a role in the setting of PJK after ASD surgery. Decreasing PT after surgery could be an element to watch out for in patients with PJK risk factors.
Patients will be randomly assigned in 1:1 ratio either to candesartan (target dose 32 mg once daily) or matching placebo. The initial dose of the study drug will be 8 mg once daily. Study drug dose will be then doubled as tolerated every 2 weeks while aiming for a target dose of 32 mg once daily. Monitoring of blood pressure, serum creatinine, serum potassium and pressure gradient in LV outflow tract will be performed during dose increase. Patients will be observed clinically at 3, 6, and 12 months after the maintenance dose was reached. Exercise tolerance will be assessed by bicycle ergometry, presence of malignant arrhythmias by Holter monitoring, extent of LV hypertrophy by 2-dimensional echocardiography, and LV outflow tract pressure gradient by Doppler echocardiography at baseline and 12-month follow-up.
Patients with Huntington’s disease are at increased risk for depression, suicidal ideation or behaviors (suicidality). Tetrabenazine increases the risk for suicidality in patients with HD.

In a 12-week, double-blind, placebo-controlled study in patients with chorea associated with Huntington’s disease, 10 of 54 patients (19%) treated with tetrabenazine tablets were reported to have an adverse event of depression or worsening depression compared to none of the 30 placebo-treated patients. In two open-label studies (in one study, 29 patients received tetrabenazine tablets for up to 48 weeks; in the second study, 75 patients received tetrabenazine tablets for up to 80 weeks), the rate of depression/worsening depression was 35%.

In all of the HD chorea studies of tetrabenazine (n=187), one patient committed suicide, one attempted suicide, and six had suicidal ideation.

When considering the use of tetrabenazine tablets, the risk of suicidality should be balanced against the need for treatment of chorea. All patients treated with tetrabenazine tablets should be observed for new or worsening depression or suicidality. If depression or suicidality does not resolve, consider discontinuing treatment with tetrabenazine tablets.

Patients, their caregivers, and families should be informed of the risks of depression, worsening depression, and suicidality associated with tetrabenazine tablets, and should be instructed to report behaviors of concern promptly to the treating physician. Patients with HD who express suicidal ideation should be evaluated immediately.
OBJECTIVE: Evaluation of course and outcome of pregnancies with prenatally diagnosed fetal urinoma in a single center over a 20-year period.
METHODS: Retrospective study including all prenatally suspected or diagnosed fetal urinomas. Cases were analyzed by ultrasound findings during pregnancy, comparing urinomas caused by lower urinary tract obstruction (LUTO) and ureteropelvic or ureterovesical junction obstruction (UPJO/UVJO). Course of pregnancy and outcomes were compared according to the underlying etiology.
RESULTS: 87 cases of fetal urinomas were identified between 2002 and 2022. The underlying etiology was LUTO in 56.3% and UPJO/UVJO in 43.7%. Complications mainly included oligo- or anhydramnios, thoracic hypoplasia as well as associated renal abnormalities. Postnatally, loss of function (LOF) in kidneys affected by urinomas was seen in 78.6% of children overall, but significantly more often in cases of UPJO/UVJO than in LUTO (86.2% vs. 70.2%, p < 0.05).
CONCLUSION: Association of prenatal urinoma and postnatal LOF of the affected kidney is high, especially in cases caused by UPJO/UVJO. In survivors with urinoma caused by UPJO/UVJO, the general prognosis is excellent if the contralateral kidney was normal. In survivors with urinomas caused by LUTO, long-term prognosis depends on postnatal renal and pulmonary function.
This invention belongs to the technical field of food nutrition and relates to an application of West Lake Brasenia schreberi extract in gastric mucosa protection. This application includes the following steps. Step 1, preparation of Brasenia schreberi powder via freeze drying. Step 2, the Brasenia schreberi powder is extracted and concentrated after adding pure water to obtain a first concentrate liquor. Step 3, the first concentrate liquor is subject to ultrafiltration to obtain a ultrafiltrate liquor. Step 4, the ultrafiltrate liquor is subject to rotary evaporation to obtain the West Lake Brasenia schreberi extract. Step 5, taking the West Lake Brasenia schreberi extract at a dose of 20 mL/day. This application can effectively concentrate the effective components of West Lake Brasenia schreberi which has a good effect in gastric mucosa protection.
Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
Patients receive an influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care (single- or dual-agent) ipilimumab, nivolumab, relatlimab, or pembrolizumab.
BACKGROUND: Operative management of midfoot Charcot arthropathy often involves an extended midfoot arthrodesis with intramedullary bolts for fixation, a method called "beaming." Recently intramedullary nails have been introduced for the same indication, presumably providing stronger fixation. This study compares midfoot fusion nails to bolts with regard to stiffness and compressive ability. Additionally, we assessed how the addition of a subtalar fusion affects the construct.
METHODS: Medial column fusions were performed on 10 matched cadaver foot specimens with either a midfoot fusion nail or bolt. Specimens underwent cyclical compression loading, and displacement was measured. Separately, compressive forces produced were compared between the 2 fixation constructs using a synthetic bone block model. Lastly, another 10 matched specimens with midfoot fusion nails were evaluated with or without subtalar fusions.
RESULTS: No differences in stiffness were found in comparing matched specimens between nail vs bolt or comparing nail only without subtalar fusion (STF) vs nail with STF. The compressive force produced by the nail specimens was significantly and substantially greater than the bolted specimens (751.7 vs 139.0 N, P = .01). The accumulated height drop at the midfoot after cycling was 0.5 mm more in the nail group than in the bolt group (1.72 vs 1.22 mm, P = .008). The nail with STF group had greater initial height drop at the midfoot than the nail-only group (0.68 vs 0.34 mm, P = .035) with similar initial height drop at the ankle. However, there were no differences in strength among the matched pairs of midfoot nail-only vs midfoot nail with STF as measured by displacement after fatigue or maximum force at load to failure.
CONCLUSION: The overall cadaveric comparisons between matched pairs of nails vs bolts, and nail-only vs nail with STF, did not provide noteworthy differences between the groups with regard to strength or stiffness. However, the compressive force of the midfoot fusion nail was far superior to the bolt in a synthetic bone model. These data provide valuable insight comparing implants used in Charcot midfoot arthrodesis.
In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
Neural invasion underlies the local spread of gastric cancer and is associated with poor prognosis. This process has been receiving increasing attention in recent years. However, the relationship between neural invasion and the malignant phenotypes of gastric cancer cells, as well as the molecular mechanism involved in this process, remain unclear. In this study, bioinformatics analysis was performed using a dataset obtained from The Cancer Genome Atlas-Stomach Adenocarcinoma. The results revealed that high expression of GDNF family receptor alpha 3 (GFRA3) was associated with a poor prognosis of patients with gastric cancer. GFRA3 is a receptor for artemin (ARTN), a glial cell line-derived neurotrophic factor (GDNF). This association was indicated by short overall/disease-free survival, as well as the presence of high-stage and high-grade disease. Gene set enrichment analysis showed that two cancer-associated pathways, namely KRAS signaling and epithelial-mesenchymal transition (EMT), were activated when GFRA3 was highly expressed in gastric cancer. Further studies confirmed that GFRA3 activated KRAS downstream signaling phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) or extracellular signal-regulated kinase (ERK) and induced EMT markers, as well as promoted the migration and invasion of gastric cancer cells. As a ligand of GFRA3, ARTN induced the EMT, migration, and invasion of gastric cancer cells via GFRA3. Notably, the effects of the ARTN-GFRA3 axis were attenuated by treatment with a KRAS inhibitor. The present findings indicated that, during the neural invasion of gastric cancer, ARTN-mediated activation of GFRA3 induces EMT phenotypes, migration, and invasion of gastric cancer cells via KRAS signaling.